The submission system has been updated — tell us of any problems

Richard Buka | GMC# 7263586

  • University of Birmingham
  • Clinical Research Fellow

Declaration on 14 June 2023

Declaration period: 2023

Main employment

  • Type: Academic
  • Details: Clinical Resear / University of Birmingham

Financial

  • Relates to: Shares, stocks or company ownership
  • Income band: £10,000 to under £50,000
  • Details: I am a director of Smartemis Limited. We founded and run www.pathquestionbank.com. This is an online revision site for doctors studying for FRCPath Haematology. I am also a director of P2B Property Limited. This is a small property business refurbishing and letting residential properties.

Declaration on 14 June 2023

Declaration period: 2023

Main employment

  • Type: Academic
  • Details: Clinical Research Fellow / University of Birmingham

Consultancy

  • Relates to: Pharmaceutical companies
  • Income band: £1,000 to under £2,000
  • Details: £990 from Bayer for 30 min talk at Expert Clotters 2023. £612.80 from Sanofi for 3.83 hours consultancy relating to improving the company's educational aim to improve awareness of thrombotic thrombocytopaenic purpura £1,528 from Sobi for 7 hours preparation and recording of educational videos on paroxysmal nocturnal haemoglobinuria

Academic

  • Relates to: Research grants
  • Income band: £50,000 to under £100,000
  • Details: I am chair of HaemSTAR, a UK charity promoting research in non-malignant haematology. Through HaemSTAR, I am running the RAPIDO project (www.haemstar.org/RAPIDO) which is funded by AstraZeneca. This funding is for costs associated with the project but not my salary. There is £5,000 allocated for travel to conferences that I intend on using, but this has not yet been used. This remains an investigator-led project and the company do not have access to the data.

Other work

  • Relates to: Media
  • Income band: £2,000 to under £5,000
  • Details: I have received royalties from Karger for writing the FastFacts book: "CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma". This had no pharmaceutical company funding.

Financial

  • Relates to: Shares, stocks or company ownership
  • Income band: £1,000 to under £2,000
  • Details: I own shares in Exelixis Inc

Something wrong with this declaration? Contact team@sunshineuk.org to let them know.